SG11201809726UA - Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist - Google Patents
Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonistInfo
- Publication number
- SG11201809726UA SG11201809726UA SG11201809726UA SG11201809726UA SG11201809726UA SG 11201809726U A SG11201809726U A SG 11201809726UA SG 11201809726U A SG11201809726U A SG 11201809726UA SG 11201809726U A SG11201809726U A SG 11201809726UA SG 11201809726U A SG11201809726U A SG 11201809726UA
- Authority
- SG
- Singapore
- Prior art keywords
- road
- telangana
- hyderabad
- serene
- life sciences
- Prior art date
Links
- 108091005435 5-HT6 receptors Proteins 0.000 title abstract 4
- 239000000544 cholinesterase inhibitor Substances 0.000 title abstract 4
- 229940099433 NMDA receptor antagonist Drugs 0.000 title abstract 3
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 title abstract 3
- 229940044551 receptor antagonist Drugs 0.000 title abstract 3
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 abstract 4
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 abstract 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229960003530 donepezil Drugs 0.000 abstract 2
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 abstract 2
- 229960004640 memantine Drugs 0.000 abstract 2
- 239000004783 Serene Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract 1
- 239000003751 serotonin 6 antagonist Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Psychiatry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201641017204 | 2016-05-18 | ||
| PCT/IB2016/054672 WO2017199070A1 (en) | 2016-05-18 | 2016-08-03 | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809726UA true SG11201809726UA (en) | 2018-12-28 |
Family
ID=56896730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809726UA SG11201809726UA (en) | 2016-05-18 | 2016-08-03 | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US11253514B2 (zh) |
| EP (1) | EP3458039B1 (zh) |
| JP (1) | JP6629464B2 (zh) |
| KR (1) | KR102016120B1 (zh) |
| CN (1) | CN109152751A (zh) |
| AU (1) | AU2016407426B2 (zh) |
| BR (1) | BR112018073410A2 (zh) |
| CA (1) | CA3023836C (zh) |
| CY (1) | CY1123644T1 (zh) |
| DK (1) | DK3458039T3 (zh) |
| EA (1) | EA038087B1 (zh) |
| ES (1) | ES2815555T3 (zh) |
| HK (1) | HK1258022A1 (zh) |
| HR (1) | HRP20201412T1 (zh) |
| HU (1) | HUE052077T2 (zh) |
| IL (1) | IL262920B (zh) |
| LT (1) | LT3458039T (zh) |
| MA (1) | MA45002B1 (zh) |
| MD (1) | MD3458039T2 (zh) |
| MX (1) | MX2018014184A (zh) |
| NZ (1) | NZ747797A (zh) |
| PL (1) | PL3458039T3 (zh) |
| PT (1) | PT3458039T (zh) |
| RS (1) | RS60849B1 (zh) |
| SG (1) | SG11201809726UA (zh) |
| SI (1) | SI3458039T1 (zh) |
| WO (1) | WO2017199070A1 (zh) |
| ZA (1) | ZA201807310B (zh) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201913104QA (en) * | 2017-07-03 | 2020-01-30 | Suven Life Sciences Ltd | New uses of a pure 5-ht 6 receptor antagonist |
| WO2021111330A1 (en) | 2019-12-02 | 2021-06-10 | Suven Life Sciences Limited | Treating behavioral and psychological symptoms in dementia patients |
| JP2023510082A (ja) * | 2019-12-02 | 2023-03-13 | スヴェン・ライフ・サイエンシーズ・リミテッド | 認知症患者における行動・心理症状を治療するための方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60324788D1 (de) * | 2002-05-31 | 2009-01-02 | Lundbeck & Co As H | Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit |
| US7875605B2 (en) | 2002-11-28 | 2011-01-25 | Suven Life Sciences Limited | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them |
| CN102869647B (zh) * | 2010-01-05 | 2015-06-24 | 苏文生命科学有限公司 | 作为5-ht6受体配体的砜化合物 |
| EA028038B1 (ru) | 2013-12-02 | 2017-09-29 | Сувен Лайф Сайенсиз Лимитед | Способ для промышленного производства 1-[(2-бромфенил)сульфонил]-5-метокси-3-[(4-метил-1-пиперазинил)метил]-1h-индол димезилат моногидрата |
| CN105085436B (zh) * | 2014-04-19 | 2019-08-16 | 广东东阳光药业有限公司 | 磺酰胺类衍生物及其在药物上的应用 |
-
2016
- 2016-08-03 JP JP2018559327A patent/JP6629464B2/ja active Active
- 2016-08-03 HU HUE16763575A patent/HUE052077T2/hu unknown
- 2016-08-03 PL PL16763575T patent/PL3458039T3/pl unknown
- 2016-08-03 US US16/097,752 patent/US11253514B2/en active Active
- 2016-08-03 RS RS20201045A patent/RS60849B1/sr unknown
- 2016-08-03 CA CA3023836A patent/CA3023836C/en active Active
- 2016-08-03 AU AU2016407426A patent/AU2016407426B2/en active Active
- 2016-08-03 ES ES16763575T patent/ES2815555T3/es active Active
- 2016-08-03 LT LTEP16763575.4T patent/LT3458039T/lt unknown
- 2016-08-03 MX MX2018014184A patent/MX2018014184A/es unknown
- 2016-08-03 MD MDE20190349T patent/MD3458039T2/ro unknown
- 2016-08-03 CN CN201680085589.7A patent/CN109152751A/zh active Pending
- 2016-08-03 SI SI201630909T patent/SI3458039T1/sl unknown
- 2016-08-03 EA EA201892528A patent/EA038087B1/ru unknown
- 2016-08-03 MA MA45002A patent/MA45002B1/fr unknown
- 2016-08-03 SG SG11201809726UA patent/SG11201809726UA/en unknown
- 2016-08-03 KR KR1020187035888A patent/KR102016120B1/ko active IP Right Grant
- 2016-08-03 BR BR112018073410-1A patent/BR112018073410A2/pt not_active Application Discontinuation
- 2016-08-03 WO PCT/IB2016/054672 patent/WO2017199070A1/en unknown
- 2016-08-03 PT PT167635754T patent/PT3458039T/pt unknown
- 2016-08-03 EP EP16763575.4A patent/EP3458039B1/en active Active
- 2016-08-03 NZ NZ747797A patent/NZ747797A/en unknown
- 2016-08-03 DK DK16763575.4T patent/DK3458039T3/da active
-
2018
- 2018-10-31 ZA ZA2018/07310A patent/ZA201807310B/en unknown
- 2018-11-11 IL IL262920A patent/IL262920B/en active IP Right Grant
-
2019
- 2019-01-10 HK HK19100393.2A patent/HK1258022A1/zh unknown
-
2020
- 2020-09-03 HR HRP20201412TT patent/HRP20201412T1/hr unknown
- 2020-09-04 CY CY20201100834T patent/CY1123644T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901525XA (en) | Muscarinic m1 receptor positive allosteric modulators | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809559UA (en) | Substituted pyridines as inhibitors of dnmt1 | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201805380YA (en) | Urea-based prostate specific membrane antigen (psma) inhibitors for imaging and therapy | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201408067YA (en) | Crystalline forms of a bruton's tyrosine kinase inhibitor | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201902886SA (en) | Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide y receptors | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201909224QA (en) | Benzoazepine analogs as inhibiting agents for bruton's tyrosine kinase | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders | |
| SG11201806393QA (en) | Use of gabaa receptor modulators for treatment of itch | |
| SG11201901070YA (en) | Formulations for oral administration of active agents | |
| SG11201809726UA (en) | Triple combination of pure 5-ht6 receptor antagonists, acetylcholinesterase inhibitors and nmda receptor antagonist | |
| SG11201809856SA (en) | Combination of pure 5-ht6 receptor antagonists with acetylcholinesterase inhibitors | |
| SG11201901999XA (en) | Crystalline forms of a lysyl oxidase-like 2 inhibitor and methods of making | |
| SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound |